# PeptideScanner evidence objects: Metreleptin

Every published version of the records placed with Metreleptin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/metreleptin.json. Selected public evidence only; not medical advice.

- Objects: 43
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00025883-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00025883

> PeptideScanner retained ClinicalTrials.gov record NCT00025883 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-08-16, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00025883-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00025883-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00025883-metreleptin-v1
- Content SHA-256: `aef5c96479a99508deb3d00a98c0313238051c21b3c1761f842a3ea948d62168`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00025883 ([`ctg-observation-nct00025883-2016-08-16-30ec99f1c298`](#source-ctg-observation-nct00025883-2016-08-16-30ec99f1c298))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00025883 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-08-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00025883-2016-08-16-30ec99f1c298`](#source-ctg-observation-nct00025883-2016-08-16-30ec99f1c298))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00025883 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-08-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00025883-2016-08-16-30ec99f1c298`](#source-ctg-observation-nct00025883-2016-08-16-30ec99f1c298))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00025883-2016-08-16-30ec99f1c298`](#source-ctg-observation-nct00025883-2016-08-16-30ec99f1c298))

### Sources

<a id="source-ctg-observation-nct00025883-2016-08-16-30ec99f1c298"></a>
- **ClinicalTrials.gov record NCT00025883 · retained source version 2016-08-16:30ec99f1c2985c0c7e59827b2131cdafda0ec7ce9a327dcb4a1e070b80acc1bc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00025883) (`ctg-observation-nct00025883-2016-08-16-30ec99f1c298`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00025883." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00025883-metreleptin-v1 SHA-256: aef5c96479a99508deb3d00a98c0313238051c21b3c1761f842a3ea948d62168.

---

<a id="clinicaltrials-gov-nct00085982-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00085982

> PeptideScanner retained ClinicalTrials.gov record NCT00085982 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-01-30, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00085982-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-01-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00085982-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00085982-metreleptin-v1
- Content SHA-256: `d917184bc1433a112d549cbbf33923a54d4aa1cf3e85e448ae0c7fd8a3f6b7d2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00085982 ([`ctg-observation-nct00085982-2025-01-30-5e83e14fad93`](#source-ctg-observation-nct00085982-2025-01-30-5e83e14fad93))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00085982 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-01-30, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00085982-2025-01-30-5e83e14fad93`](#source-ctg-observation-nct00085982-2025-01-30-5e83e14fad93))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00085982 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-01-30, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00085982-2025-01-30-5e83e14fad93`](#source-ctg-observation-nct00085982-2025-01-30-5e83e14fad93))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00085982-2025-01-30-5e83e14fad93`](#source-ctg-observation-nct00085982-2025-01-30-5e83e14fad93))

### Sources

<a id="source-ctg-observation-nct00085982-2025-01-30-5e83e14fad93"></a>
- **ClinicalTrials.gov record NCT00085982 · retained source version 2025-01-30:5e83e14fad935953cf05e9878067b7f78159bfec0d7b6f269c2fd533a552a413** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00085982) (`ctg-observation-nct00085982-2025-01-30-5e83e14fad93`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00085982." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00085982-metreleptin-v1 SHA-256: d917184bc1433a112d549cbbf33923a54d4aa1cf3e85e448ae0c7fd8a3f6b7d2.

---

<a id="clinicaltrials-gov-nct00130117-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00130117

> PeptideScanner retained ClinicalTrials.gov record NCT00130117 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-05-17, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00130117-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00130117-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00130117-metreleptin-v1
- Content SHA-256: `e1f9a974709c602023e48c67d023a93b4699d4b44a2282e0fdc117cf10ee4e23`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00130117 ([`ctg-observation-nct00130117-2017-05-17-2dd3c456e100`](#source-ctg-observation-nct00130117-2017-05-17-2dd3c456e100))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00130117 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-05-17, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00130117-2017-05-17-2dd3c456e100`](#source-ctg-observation-nct00130117-2017-05-17-2dd3c456e100))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00130117 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-05-17, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00130117-2017-05-17-2dd3c456e100`](#source-ctg-observation-nct00130117-2017-05-17-2dd3c456e100))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00130117-2017-05-17-2dd3c456e100`](#source-ctg-observation-nct00130117-2017-05-17-2dd3c456e100))

### Sources

<a id="source-ctg-observation-nct00130117-2017-05-17-2dd3c456e100"></a>
- **ClinicalTrials.gov record NCT00130117 · retained source version 2017-05-17:2dd3c456e100b90828e6a2ecfc75d71b85bd512658d8a49e6538b9cdc98f65bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00130117) (`ctg-observation-nct00130117-2017-05-17-2dd3c456e100`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00130117." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00130117-metreleptin-v1 SHA-256: e1f9a974709c602023e48c67d023a93b4699d4b44a2282e0fdc117cf10ee4e23.

---

<a id="clinicaltrials-gov-nct00140231-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00140231

> PeptideScanner retained ClinicalTrials.gov record NCT00140231 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-07, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00140231-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00140231-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00140231-metreleptin-v1
- Content SHA-256: `d347930aba043cd971841f377877fdb06c49a1b090016555d776207b187a01bf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00140231 ([`ctg-observation-nct00140231-2017-06-07-e20033ea23cd`](#source-ctg-observation-nct00140231-2017-06-07-e20033ea23cd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00140231 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-07, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00140231-2017-06-07-e20033ea23cd`](#source-ctg-observation-nct00140231-2017-06-07-e20033ea23cd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00140231 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-07, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00140231-2017-06-07-e20033ea23cd`](#source-ctg-observation-nct00140231-2017-06-07-e20033ea23cd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00140231-2017-06-07-e20033ea23cd`](#source-ctg-observation-nct00140231-2017-06-07-e20033ea23cd))

### Sources

<a id="source-ctg-observation-nct00140231-2017-06-07-e20033ea23cd"></a>
- **ClinicalTrials.gov record NCT00140231 · retained source version 2017-06-07:e20033ea23cd2653b0f6ecfceea51beb7078e33a833e37fa18ef7b5a39be08d1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00140231) (`ctg-observation-nct00140231-2017-06-07-e20033ea23cd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00140231." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00140231-metreleptin-v1 SHA-256: d347930aba043cd971841f377877fdb06c49a1b090016555d776207b187a01bf.

---

<a id="clinicaltrials-gov-nct00392925-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00392925

> PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00392925-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00392925-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00392925-metreleptin-v1
- Content SHA-256: `bc252e6f5d3217e622eb3e7d89e7decbdecedceb8582ae8369bfc7c85f10bca1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00392925 ([`ctg-observation-nct00392925-2015-04-14-d632c3d667a5`](#source-ctg-observation-nct00392925-2015-04-14-d632c3d667a5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00392925-2015-04-14-d632c3d667a5`](#source-ctg-observation-nct00392925-2015-04-14-d632c3d667a5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00392925-2015-04-14-d632c3d667a5`](#source-ctg-observation-nct00392925-2015-04-14-d632c3d667a5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00392925-2015-04-14-d632c3d667a5`](#source-ctg-observation-nct00392925-2015-04-14-d632c3d667a5))

### Sources

<a id="source-ctg-observation-nct00392925-2015-04-14-d632c3d667a5"></a>
- **ClinicalTrials.gov record NCT00392925 · retained source version 2015-04-14:d632c3d667a558ca6a999d77210bbef7640a6d52318266abd22cf55f97d00a92** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00392925) (`ctg-observation-nct00392925-2015-04-14-d632c3d667a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00392925." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00392925-metreleptin-v1 SHA-256: bc252e6f5d3217e622eb3e7d89e7decbdecedceb8582ae8369bfc7c85f10bca1.

---

<a id="clinicaltrials-gov-nct00461552-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00461552

> PeptideScanner retained ClinicalTrials.gov record NCT00461552 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-05-09, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00461552-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-05-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00461552-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00461552-metreleptin-v1
- Content SHA-256: `49eb7f1de68c42e8a83a57b31485d75ce74859e20f08d279512ee5cf133d48cb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00461552 ([`ctg-observation-nct00461552-2019-05-09-f34e4799ef58`](#source-ctg-observation-nct00461552-2019-05-09-f34e4799ef58))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00461552 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-05-09, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00461552-2019-05-09-f34e4799ef58`](#source-ctg-observation-nct00461552-2019-05-09-f34e4799ef58))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00461552 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-05-09, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00461552-2019-05-09-f34e4799ef58`](#source-ctg-observation-nct00461552-2019-05-09-f34e4799ef58))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00461552-2019-05-09-f34e4799ef58`](#source-ctg-observation-nct00461552-2019-05-09-f34e4799ef58))

### Sources

<a id="source-ctg-observation-nct00461552-2019-05-09-f34e4799ef58"></a>
- **ClinicalTrials.gov record NCT00461552 · retained source version 2019-05-09:f34e4799ef5876152b56a1b6d5e923e2a2a076d70f4cac6083f8d585146b51f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00461552) (`ctg-observation-nct00461552-2019-05-09-f34e4799ef58`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00461552." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00461552-metreleptin-v1 SHA-256: 49eb7f1de68c42e8a83a57b31485d75ce74859e20f08d279512ee5cf133d48cb.

---

<a id="clinicaltrials-gov-nct00596934-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00596934

> PeptideScanner retained ClinicalTrials.gov record NCT00596934 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00596934-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-11-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00596934-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00596934-metreleptin-v1
- Content SHA-256: `1081b2c460cb760e10241f9ee01ee5e806ce4e9893ce8b70eb9b04135bfaed75`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00596934 ([`ctg-observation-nct00596934-2017-11-24-630304b260f5`](#source-ctg-observation-nct00596934-2017-11-24-630304b260f5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00596934 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00596934-2017-11-24-630304b260f5`](#source-ctg-observation-nct00596934-2017-11-24-630304b260f5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00596934 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00596934-2017-11-24-630304b260f5`](#source-ctg-observation-nct00596934-2017-11-24-630304b260f5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00596934-2017-11-24-630304b260f5`](#source-ctg-observation-nct00596934-2017-11-24-630304b260f5))

### Sources

<a id="source-ctg-observation-nct00596934-2017-11-24-630304b260f5"></a>
- **ClinicalTrials.gov record NCT00596934 · retained source version 2017-11-24:630304b260f5a0c7fdcd9d9f4f49f5c6465786cfe4aa3e371c382bbe7d151858** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00596934) (`ctg-observation-nct00596934-2017-11-24-630304b260f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00596934." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00596934-metreleptin-v1 SHA-256: 1081b2c460cb760e10241f9ee01ee5e806ce4e9893ce8b70eb9b04135bfaed75.

---

<a id="clinicaltrials-gov-nct00657605-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00657605

> PeptideScanner retained ClinicalTrials.gov record NCT00657605 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00657605-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00657605-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00657605-metreleptin-v1
- Content SHA-256: `6668f35d37ebf4c7a49920344d60bf4928690dbea37ab3935d6acdd8795b6a89`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00657605 ([`ctg-observation-nct00657605-2020-02-13-16e7cec66cee`](#source-ctg-observation-nct00657605-2020-02-13-16e7cec66cee))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00657605 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00657605-2020-02-13-16e7cec66cee`](#source-ctg-observation-nct00657605-2020-02-13-16e7cec66cee))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00657605 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00657605-2020-02-13-16e7cec66cee`](#source-ctg-observation-nct00657605-2020-02-13-16e7cec66cee))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00657605-2020-02-13-16e7cec66cee`](#source-ctg-observation-nct00657605-2020-02-13-16e7cec66cee))

### Sources

<a id="source-ctg-observation-nct00657605-2020-02-13-16e7cec66cee"></a>
- **ClinicalTrials.gov record NCT00657605 · retained source version 2020-02-13:16e7cec66cee86aa9008d0ee3a87fff2fc8d1c8cfe109b584aca51adc6628721** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00657605) (`ctg-observation-nct00657605-2020-02-13-16e7cec66cee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00657605." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00657605-metreleptin-v1 SHA-256: 6668f35d37ebf4c7a49920344d60bf4928690dbea37ab3935d6acdd8795b6a89.

---

<a id="clinicaltrials-gov-nct00659828-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00659828

> PeptideScanner retained ClinicalTrials.gov record NCT00659828 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00659828-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00659828-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00659828-metreleptin-v1
- Content SHA-256: `7f59ec1c6d61e5ddb6a431b383332975ba82e1aeda8d92e35c84d0c7fd601662`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00659828 ([`ctg-observation-nct00659828-2020-02-13-b7a97bd48066`](#source-ctg-observation-nct00659828-2020-02-13-b7a97bd48066))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00659828 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00659828-2020-02-13-b7a97bd48066`](#source-ctg-observation-nct00659828-2020-02-13-b7a97bd48066))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00659828 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00659828-2020-02-13-b7a97bd48066`](#source-ctg-observation-nct00659828-2020-02-13-b7a97bd48066))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00659828-2020-02-13-b7a97bd48066`](#source-ctg-observation-nct00659828-2020-02-13-b7a97bd48066))

### Sources

<a id="source-ctg-observation-nct00659828-2020-02-13-b7a97bd48066"></a>
- **ClinicalTrials.gov record NCT00659828 · retained source version 2020-02-13:b7a97bd4806619e9d3dcac2011d0dff6c011bf2ad8d6761dfac2b9609d722dd0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00659828) (`ctg-observation-nct00659828-2020-02-13-b7a97bd48066`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00659828." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00659828-metreleptin-v1 SHA-256: 7f59ec1c6d61e5ddb6a431b383332975ba82e1aeda8d92e35c84d0c7fd601662.

---

<a id="clinicaltrials-gov-nct00673387-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00673387

> PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00673387-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00673387-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00673387-metreleptin-v1
- Content SHA-256: `ba446e8de80e28f0479375cb2d185113f1c7f9efecd058930fa7582a240731e1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00673387 ([`ctg-observation-nct00673387-2015-04-15-f63d30b51336`](#source-ctg-observation-nct00673387-2015-04-15-f63d30b51336))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00673387-2015-04-15-f63d30b51336`](#source-ctg-observation-nct00673387-2015-04-15-f63d30b51336))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00673387-2015-04-15-f63d30b51336`](#source-ctg-observation-nct00673387-2015-04-15-f63d30b51336))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00673387-2015-04-15-f63d30b51336`](#source-ctg-observation-nct00673387-2015-04-15-f63d30b51336))

### Sources

<a id="source-ctg-observation-nct00673387-2015-04-15-f63d30b51336"></a>
- **ClinicalTrials.gov record NCT00673387 · retained source version 2015-04-15:f63d30b5133670a7deb3d8244dafa0521caa62503abfbb258db5aa85ea3eb168** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00673387) (`ctg-observation-nct00673387-2015-04-15-f63d30b51336`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00673387." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00673387-metreleptin-v1 SHA-256: ba446e8de80e28f0479375cb2d185113f1c7f9efecd058930fa7582a240731e1.

---

<a id="clinicaltrials-gov-nct00710814-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT00710814

> PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct00710814-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00710814-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00710814-metreleptin-v1
- Content SHA-256: `ed3496c7d0ccc5f01e440c68df3628b73da5f8a6805277ef721a146a444bac2c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00710814 ([`ctg-observation-nct00710814-2015-11-16-b95d092ec7dd`](#source-ctg-observation-nct00710814-2015-11-16-b95d092ec7dd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00710814-2015-11-16-b95d092ec7dd`](#source-ctg-observation-nct00710814-2015-11-16-b95d092ec7dd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct00710814-2015-11-16-b95d092ec7dd`](#source-ctg-observation-nct00710814-2015-11-16-b95d092ec7dd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00710814-2015-11-16-b95d092ec7dd`](#source-ctg-observation-nct00710814-2015-11-16-b95d092ec7dd))

### Sources

<a id="source-ctg-observation-nct00710814-2015-11-16-b95d092ec7dd"></a>
- **ClinicalTrials.gov record NCT00710814 · retained source version 2015-11-16:b95d092ec7ddfac5418f1a0abae781712da62d1de3c3f2df1467842f22b49642** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00710814) (`ctg-observation-nct00710814-2015-11-16-b95d092ec7dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00710814." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct00710814-metreleptin-v1 SHA-256: ed3496c7d0ccc5f01e440c68df3628b73da5f8a6805277ef721a146a444bac2c.

---

<a id="clinicaltrials-gov-nct01155180-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT01155180

> PeptideScanner retained ClinicalTrials.gov record NCT01155180 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct01155180-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01155180-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01155180-metreleptin-v1
- Content SHA-256: `d43fd503534b3f81eb11b9f6c69973d2323d28c8369d7bd4582d37e0d1851b08`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01155180 ([`ctg-observation-nct01155180-2017-04-07-6a316433120f`](#source-ctg-observation-nct01155180-2017-04-07-6a316433120f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01155180 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01155180-2017-04-07-6a316433120f`](#source-ctg-observation-nct01155180-2017-04-07-6a316433120f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01155180 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01155180-2017-04-07-6a316433120f`](#source-ctg-observation-nct01155180-2017-04-07-6a316433120f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01155180-2017-04-07-6a316433120f`](#source-ctg-observation-nct01155180-2017-04-07-6a316433120f))

### Sources

<a id="source-ctg-observation-nct01155180-2017-04-07-6a316433120f"></a>
- **ClinicalTrials.gov record NCT01155180 · retained source version 2017-04-07:6a316433120f369a491798124cf1c937dced573423d0d6be0b1935196f2a702c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01155180) (`ctg-observation-nct01155180-2017-04-07-6a316433120f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01155180." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01155180-metreleptin-v1 SHA-256: d43fd503534b3f81eb11b9f6c69973d2323d28c8369d7bd4582d37e0d1851b08.

---

<a id="clinicaltrials-gov-nct01511016-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT01511016

> PeptideScanner retained ClinicalTrials.gov record NCT01511016 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct01511016-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01511016-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01511016-metreleptin-v1
- Content SHA-256: `d4634829bab464f0fea0ea74534eb9728bb865b6c26d7e565fc730b6f4b54485`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01511016 ([`ctg-observation-nct01511016-2016-01-27-e7a0a06ac357`](#source-ctg-observation-nct01511016-2016-01-27-e7a0a06ac357))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01511016 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01511016-2016-01-27-e7a0a06ac357`](#source-ctg-observation-nct01511016-2016-01-27-e7a0a06ac357))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01511016 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01511016-2016-01-27-e7a0a06ac357`](#source-ctg-observation-nct01511016-2016-01-27-e7a0a06ac357))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01511016-2016-01-27-e7a0a06ac357`](#source-ctg-observation-nct01511016-2016-01-27-e7a0a06ac357))

### Sources

<a id="source-ctg-observation-nct01511016-2016-01-27-e7a0a06ac357"></a>
- **ClinicalTrials.gov record NCT01511016 · retained source version 2016-01-27:e7a0a06ac357bb7e995ea6ecbf589c5d7a9a50a0d58f0abb97968e62437ea36f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01511016) (`ctg-observation-nct01511016-2016-01-27-e7a0a06ac357`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01511016." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01511016-metreleptin-v1 SHA-256: d4634829bab464f0fea0ea74534eb9728bb865b6c26d7e565fc730b6f4b54485.

---

<a id="clinicaltrials-gov-nct01679197-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT01679197

> PeptideScanner retained ClinicalTrials.gov record NCT01679197 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct01679197-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01679197-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01679197-metreleptin-v1
- Content SHA-256: `35e28cd80805c7e17272186ec94c98c33ae0a54b44ec0351cf517dd0c3dc50fe`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01679197 ([`ctg-observation-nct01679197-2017-06-14-707f672e4db3`](#source-ctg-observation-nct01679197-2017-06-14-707f672e4db3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01679197 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01679197-2017-06-14-707f672e4db3`](#source-ctg-observation-nct01679197-2017-06-14-707f672e4db3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01679197 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01679197-2017-06-14-707f672e4db3`](#source-ctg-observation-nct01679197-2017-06-14-707f672e4db3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01679197-2017-06-14-707f672e4db3`](#source-ctg-observation-nct01679197-2017-06-14-707f672e4db3))

### Sources

<a id="source-ctg-observation-nct01679197-2017-06-14-707f672e4db3"></a>
- **ClinicalTrials.gov record NCT01679197 · retained source version 2017-06-14:707f672e4db38466c27f0ededfed7eafbb8b8834345cbc27dfe6e30efab05930** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01679197) (`ctg-observation-nct01679197-2017-06-14-707f672e4db3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01679197." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01679197-metreleptin-v1 SHA-256: 35e28cd80805c7e17272186ec94c98c33ae0a54b44ec0351cf517dd0c3dc50fe.

---

<a id="clinicaltrials-gov-nct01778556-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT01778556

> PeptideScanner retained ClinicalTrials.gov record NCT01778556 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-11-13, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct01778556-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01778556-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01778556-metreleptin-v1
- Content SHA-256: `9635b0c7274a447b251c62b20a1d29aaa6413a73020199c9f6b8ad61b4a5a416`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01778556 ([`ctg-observation-nct01778556-2019-11-13-e13e4224f30c`](#source-ctg-observation-nct01778556-2019-11-13-e13e4224f30c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01778556 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-11-13, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01778556-2019-11-13-e13e4224f30c`](#source-ctg-observation-nct01778556-2019-11-13-e13e4224f30c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01778556 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-11-13, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct01778556-2019-11-13-e13e4224f30c`](#source-ctg-observation-nct01778556-2019-11-13-e13e4224f30c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01778556-2019-11-13-e13e4224f30c`](#source-ctg-observation-nct01778556-2019-11-13-e13e4224f30c))

### Sources

<a id="source-ctg-observation-nct01778556-2019-11-13-e13e4224f30c"></a>
- **ClinicalTrials.gov record NCT01778556 · retained source version 2019-11-13:e13e4224f30c708a03a18c91978613865dd84e71816e30793dbb81888d299789** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01778556) (`ctg-observation-nct01778556-2019-11-13-e13e4224f30c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01778556." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct01778556-metreleptin-v1 SHA-256: 9635b0c7274a447b251c62b20a1d29aaa6413a73020199c9f6b8ad61b4a5a416.

---

<a id="clinicaltrials-gov-nct02262806-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT02262806

> PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct02262806-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02262806-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02262806-metreleptin-v1
- Content SHA-256: `eef2844ad6c928e80b4adfc049da1316e2acd6817c2bdf5dad9ad015aad28157`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02262806 ([`ctg-observation-nct02262806-2026-11-09-4afeebdf1d95`](#source-ctg-observation-nct02262806-2026-11-09-4afeebdf1d95))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02262806-2026-11-09-4afeebdf1d95`](#source-ctg-observation-nct02262806-2026-11-09-4afeebdf1d95))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02262806-2026-11-09-4afeebdf1d95`](#source-ctg-observation-nct02262806-2026-11-09-4afeebdf1d95))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02262806-2026-11-09-4afeebdf1d95`](#source-ctg-observation-nct02262806-2026-11-09-4afeebdf1d95))

### Sources

<a id="source-ctg-observation-nct02262806-2026-11-09-4afeebdf1d95"></a>
- **ClinicalTrials.gov record NCT02262806 · retained source version 2026-11-09:4afeebdf1d959d401291774cfe7fed2aec879d2b2c004c8f7c7b95a77d78b53d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02262806) (`ctg-observation-nct02262806-2026-11-09-4afeebdf1d95`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02262806." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02262806-metreleptin-v1 SHA-256: eef2844ad6c928e80b4adfc049da1316e2acd6817c2bdf5dad9ad015aad28157.

---

<a id="clinicaltrials-gov-nct02262832-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT02262832

> PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct02262832-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02262832-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02262832-metreleptin-v1
- Content SHA-256: `adf1dea5569b718edaa5aaa7db16ee27e4ea42fed05a877794f92a22e5518816`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02262832 ([`ctg-observation-nct02262832-2026-10-27-509810967c2f`](#source-ctg-observation-nct02262832-2026-10-27-509810967c2f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02262832-2026-10-27-509810967c2f`](#source-ctg-observation-nct02262832-2026-10-27-509810967c2f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02262832-2026-10-27-509810967c2f`](#source-ctg-observation-nct02262832-2026-10-27-509810967c2f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02262832-2026-10-27-509810967c2f`](#source-ctg-observation-nct02262832-2026-10-27-509810967c2f))

### Sources

<a id="source-ctg-observation-nct02262832-2026-10-27-509810967c2f"></a>
- **ClinicalTrials.gov record NCT02262832 · retained source version 2026-10-27:509810967c2f0a755a6f87b1cef66ef1ccc6d6190435151ea699edc98280879a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02262832) (`ctg-observation-nct02262832-2026-10-27-509810967c2f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02262832." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02262832-metreleptin-v1 SHA-256: adf1dea5569b718edaa5aaa7db16ee27e4ea42fed05a877794f92a22e5518816.

---

<a id="clinicaltrials-gov-nct02325674-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT02325674

> PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct02325674-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02325674-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02325674-metreleptin-v1
- Content SHA-256: `0ba8eac8600d96fac0cfcc57b69c06d06344340e3d730cb0e39d3eb91975f4a3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02325674 ([`ctg-observation-nct02325674-2026-07-16-6d7440a41180`](#source-ctg-observation-nct02325674-2026-07-16-6d7440a41180))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02325674-2026-07-16-6d7440a41180`](#source-ctg-observation-nct02325674-2026-07-16-6d7440a41180))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02325674-2026-07-16-6d7440a41180`](#source-ctg-observation-nct02325674-2026-07-16-6d7440a41180))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02325674-2026-07-16-6d7440a41180`](#source-ctg-observation-nct02325674-2026-07-16-6d7440a41180))

### Sources

<a id="source-ctg-observation-nct02325674-2026-07-16-6d7440a41180"></a>
- **ClinicalTrials.gov record NCT02325674 · retained source version 2026-07-16:6d7440a41180343499c88bfe48ec6419d3daec350f056a3844038081d9634f08** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02325674) (`ctg-observation-nct02325674-2026-07-16-6d7440a41180`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02325674." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02325674-metreleptin-v1 SHA-256: 0ba8eac8600d96fac0cfcc57b69c06d06344340e3d730cb0e39d3eb91975f4a3.

---

<a id="clinicaltrials-gov-nct02654977-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT02654977

> PeptideScanner retained ClinicalTrials.gov record NCT02654977 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct02654977-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-11-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02654977-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02654977-metreleptin-v1
- Content SHA-256: `20f75a334bc26f7f0fc89bf0468d7dd090e4fa6bf6d1baa3f62bec2486a5cc3a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02654977 ([`ctg-observation-nct02654977-2020-11-24-d105bfa34682`](#source-ctg-observation-nct02654977-2020-11-24-d105bfa34682))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02654977 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-11-24, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02654977-2020-11-24-d105bfa34682`](#source-ctg-observation-nct02654977-2020-11-24-d105bfa34682))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02654977 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-11-24, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct02654977-2020-11-24-d105bfa34682`](#source-ctg-observation-nct02654977-2020-11-24-d105bfa34682))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02654977-2020-11-24-d105bfa34682`](#source-ctg-observation-nct02654977-2020-11-24-d105bfa34682))

### Sources

<a id="source-ctg-observation-nct02654977-2020-11-24-d105bfa34682"></a>
- **ClinicalTrials.gov record NCT02654977 · retained source version 2020-11-24:d105bfa34682036f00af949438cd17751fe6ef6b6e37a106d5680f31d9aefdbe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02654977) (`ctg-observation-nct02654977-2020-11-24-d105bfa34682`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02654977." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct02654977-metreleptin-v1 SHA-256: 20f75a334bc26f7f0fc89bf0468d7dd090e4fa6bf6d1baa3f62bec2486a5cc3a.

---

<a id="clinicaltrials-gov-nct04026178-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT04026178

> PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct04026178-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04026178-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct04026178-metreleptin-v1
- Content SHA-256: `f36251c4619321f7ea5bbe8f0c7f855e209bbb9b4c796f9aedfc4821e92d0b44`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04026178 ([`ctg-observation-nct04026178-2025-11-26-dc2eec706ede`](#source-ctg-observation-nct04026178-2025-11-26-dc2eec706ede))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct04026178-2025-11-26-dc2eec706ede`](#source-ctg-observation-nct04026178-2025-11-26-dc2eec706ede))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct04026178-2025-11-26-dc2eec706ede`](#source-ctg-observation-nct04026178-2025-11-26-dc2eec706ede))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04026178-2025-11-26-dc2eec706ede`](#source-ctg-observation-nct04026178-2025-11-26-dc2eec706ede))

### Sources

<a id="source-ctg-observation-nct04026178-2025-11-26-dc2eec706ede"></a>
- **ClinicalTrials.gov record NCT04026178 · retained source version 2025-11-26:dc2eec706edec09fc2eef8e11e604a0b3af5539d624b12785d156ff34885382c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04026178) (`ctg-observation-nct04026178-2025-11-26-dc2eec706ede`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04026178." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct04026178-metreleptin-v1 SHA-256: f36251c4619321f7ea5bbe8f0c7f855e209bbb9b4c796f9aedfc4821e92d0b44.

---

<a id="clinicaltrials-gov-nct05164341-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT05164341

> PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct05164341-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05164341-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct05164341-metreleptin-v1
- Content SHA-256: `147977ce8c1385eea8312338538bb1641e4d193826cb4ba9b18674ada8e9c012`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05164341 ([`ctg-observation-nct05164341-2026-11-09-71bbae988874`](#source-ctg-observation-nct05164341-2026-11-09-71bbae988874))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct05164341-2026-11-09-71bbae988874`](#source-ctg-observation-nct05164341-2026-11-09-71bbae988874))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct05164341-2026-11-09-71bbae988874`](#source-ctg-observation-nct05164341-2026-11-09-71bbae988874))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05164341-2026-11-09-71bbae988874`](#source-ctg-observation-nct05164341-2026-11-09-71bbae988874))

### Sources

<a id="source-ctg-observation-nct05164341-2026-11-09-71bbae988874"></a>
- **ClinicalTrials.gov record NCT05164341 · retained source version 2026-11-09:71bbae9888741c75e3b59073f27c20864de7a3f0bb3809c6ccfa74fccfc81fde** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05164341) (`ctg-observation-nct05164341-2026-11-09-71bbae988874`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05164341." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct05164341-metreleptin-v1 SHA-256: 147977ce8c1385eea8312338538bb1641e4d193826cb4ba9b18674ada8e9c012.

---

<a id="clinicaltrials-gov-nct05351164-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT05351164

> PeptideScanner retained ClinicalTrials.gov record NCT05351164 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct05351164-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05351164-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct05351164-metreleptin-v1
- Content SHA-256: `937243869aa65e53ad09599cfa935bcdfec6ee902a75975c800186120d96f028`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05351164 ([`ctg-observation-nct05351164-2025-06-12-6c50d4786740`](#source-ctg-observation-nct05351164-2025-06-12-6c50d4786740))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05351164 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct05351164-2025-06-12-6c50d4786740`](#source-ctg-observation-nct05351164-2025-06-12-6c50d4786740))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05351164 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct05351164-2025-06-12-6c50d4786740`](#source-ctg-observation-nct05351164-2025-06-12-6c50d4786740))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05351164-2025-06-12-6c50d4786740`](#source-ctg-observation-nct05351164-2025-06-12-6c50d4786740))

### Sources

<a id="source-ctg-observation-nct05351164-2025-06-12-6c50d4786740"></a>
- **ClinicalTrials.gov record NCT05351164 · retained source version 2025-06-12:6c50d4786740627d16b56d20f733c03347be67d1c336e14e177411f9bc83f0a7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05351164) (`ctg-observation-nct05351164-2025-06-12-6c50d4786740`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05351164." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct05351164-metreleptin-v1 SHA-256: 937243869aa65e53ad09599cfa935bcdfec6ee902a75975c800186120d96f028.

---

<a id="clinicaltrials-gov-nct06305182-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT06305182

> PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct06305182-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06305182-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct06305182-metreleptin-v1
- Content SHA-256: `826b77b94d0615a21afb32098e0826ca77741ca9367b9d0b2ed856fda1c5118f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06305182 ([`ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5`](#source-ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5`](#source-ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5`](#source-ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5`](#source-ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5))

### Sources

<a id="source-ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5"></a>
- **ClinicalTrials.gov record NCT06305182 · retained source version 2026-07-29:f98c7f9b28c53ffd11978b3d548c276e6bbb7ddc37d1428d4963f5fb07385e8e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06305182) (`ctg-observation-nct06305182-2026-07-29-f98c7f9b28c5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06305182." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct06305182-metreleptin-v1 SHA-256: 826b77b94d0615a21afb32098e0826ca77741ca9367b9d0b2ed856fda1c5118f.

---

<a id="clinicaltrials-gov-nct06484868-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT06484868

> PeptideScanner retained ClinicalTrials.gov record NCT06484868 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct06484868-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06484868-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct06484868-metreleptin-v1
- Content SHA-256: `bca3a05639439ea03de87f26d426fd38fa6785a350d8bcbc63860616e4306600`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06484868 ([`ctg-observation-nct06484868-2025-07-03-dd660667f085`](#source-ctg-observation-nct06484868-2025-07-03-dd660667f085))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06484868 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct06484868-2025-07-03-dd660667f085`](#source-ctg-observation-nct06484868-2025-07-03-dd660667f085))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06484868 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct06484868-2025-07-03-dd660667f085`](#source-ctg-observation-nct06484868-2025-07-03-dd660667f085))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06484868-2025-07-03-dd660667f085`](#source-ctg-observation-nct06484868-2025-07-03-dd660667f085))

### Sources

<a id="source-ctg-observation-nct06484868-2025-07-03-dd660667f085"></a>
- **ClinicalTrials.gov record NCT06484868 · retained source version 2025-07-03:dd660667f085589fb3dc7d3c255d70f5036c30404f4a4c4289813002a2472412** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06484868) (`ctg-observation-nct06484868-2025-07-03-dd660667f085`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06484868." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct06484868-metreleptin-v1 SHA-256: bca3a05639439ea03de87f26d426fd38fa6785a350d8bcbc63860616e4306600.

---

<a id="clinicaltrials-gov-nct06679270-metreleptin-v1"></a>

## ClinicalTrials.gov record NCT06679270

> PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.

- Evidence object: `story:clinicaltrials-gov-nct06679270-metreleptin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06679270-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct06679270-metreleptin-v1
- Content SHA-256: `7ef43fa0a771e3006fdc780173a3724a569fcbe0f8b079bab710071cb8a3a82f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06679270 ([`ctg-observation-nct06679270-2026-07-16-84a988a5e075`](#source-ctg-observation-nct06679270-2026-07-16-84a988a5e075))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct06679270-2026-07-16-84a988a5e075`](#source-ctg-observation-nct06679270-2026-07-16-84a988a5e075))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin. ([`ctg-observation-nct06679270-2026-07-16-84a988a5e075`](#source-ctg-observation-nct06679270-2026-07-16-84a988a5e075))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06679270-2026-07-16-84a988a5e075`](#source-ctg-observation-nct06679270-2026-07-16-84a988a5e075))

### Sources

<a id="source-ctg-observation-nct06679270-2026-07-16-84a988a5e075"></a>
- **ClinicalTrials.gov record NCT06679270 · retained source version 2026-07-16:84a988a5e075bedd1192e481f00909c6d79b3f8baa679a53e46ac5a24e1fb8e8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06679270) (`ctg-observation-nct06679270-2026-07-16-84a988a5e075`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06679270." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#clinicaltrials-gov-nct06679270-metreleptin-v1 SHA-256: 7ef43fa0a771e3006fdc780173a3724a569fcbe0f8b079bab710071cb8a3a82f.

---

<a id="fda-drugs-bla125390-v1"></a>

## Drugs@FDA application BLA125390

> The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-bla125390:v1`
- Evidence domain: Regulatory
- Date in source: 2014-02-24
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-bla125390/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#fda-drugs-bla125390-v1
- Content SHA-256: `c416f3333b101cadf855f73abd4c5ca3aa19182b99e2f18d480e102b779282b2`

### Claims and source pins

#### Headline

Drugs@FDA application BLA125390 ([`fda-drugs-bla125390-2014-02-24-ba456d7f94d7`](#source-fda-drugs-bla125390-2014-02-24-ba456d7f94d7))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients. ([`fda-drugs-bla125390-2014-02-24-ba456d7f94d7`](#source-fda-drugs-bla125390-2014-02-24-ba456d7f94d7))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients. ([`fda-drugs-bla125390-2014-02-24-ba456d7f94d7`](#source-fda-drugs-bla125390-2014-02-24-ba456d7f94d7))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-bla125390-2014-02-24-ba456d7f94d7`](#source-fda-drugs-bla125390-2014-02-24-ba456d7f94d7))

### Sources

<a id="source-fda-drugs-bla125390-2014-02-24-ba456d7f94d7"></a>
- **Drugs@FDA application BLA125390 · original submission status AP · 2014-02-24 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA125390%22&limit=1) (`fda-drugs-bla125390-2014-02-24-ba456d7f94d7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application BLA125390." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#fda-drugs-bla125390-v1 SHA-256: c416f3333b101cadf855f73abd4c5ca3aa19182b99e2f18d480e102b779282b2.

---

<a id="federal-register-2013-25588-v1"></a>

## Federal Register notice 2013-25588

> The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.

- Evidence object: `story:federal-register-2013-25588:v1`
- Evidence domain: Regulatory
- Date in source: 2013-10-30
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2013-25588/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#federal-register-2013-25588-v1
- Content SHA-256: `f557b1aff56b5a23e39f46b3b06fc3360cbfb08707f40dfada8e380398a0b43b`

### Claims and source pins

#### Headline

Federal Register notice 2013-25588 ([`federal-register-2013-25588-0f614a94a390`](#source-federal-register-2013-25588-0f614a94a390))

#### Summary

The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin. ([`federal-register-2013-25588-0f614a94a390`](#source-federal-register-2013-25588-0f614a94a390))

#### Paragraph 1

The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin. ([`federal-register-2013-25588-0f614a94a390`](#source-federal-register-2013-25588-0f614a94a390))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2013-25588-0f614a94a390`](#source-federal-register-2013-25588-0f614a94a390))

### Sources

<a id="source-federal-register-2013-25588-0f614a94a390"></a>
- **Federal Register notice 2013-25588 · published 2013-10-30 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2013-10-30/pdf/2013-25588.pdf) (`federal-register-2013-25588-0f614a94a390`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2013-25588." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#federal-register-2013-25588-v1 SHA-256: f557b1aff56b5a23e39f46b3b06fc3360cbfb08707f40dfada8e380398a0b43b.

---

<a id="federal-register-2016-22935-v1"></a>

## Federal Register notice 2016-22935

> The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.

- Evidence object: `story:federal-register-2016-22935:v1`
- Evidence domain: Regulatory
- Date in source: 2016-09-23
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-22935/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#federal-register-2016-22935-v1
- Content SHA-256: `3c5ba1f5e955dc81306a6482e18f060a3f38243345fd24168f712fd122656db0`

### Claims and source pins

#### Headline

Federal Register notice 2016-22935 ([`federal-register-2016-22935-6e9cbee524d2`](#source-federal-register-2016-22935-6e9cbee524d2))

#### Summary

The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin. ([`federal-register-2016-22935-6e9cbee524d2`](#source-federal-register-2016-22935-6e9cbee524d2))

#### Paragraph 1

The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin. ([`federal-register-2016-22935-6e9cbee524d2`](#source-federal-register-2016-22935-6e9cbee524d2))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-22935-6e9cbee524d2`](#source-federal-register-2016-22935-6e9cbee524d2))

### Sources

<a id="source-federal-register-2016-22935-6e9cbee524d2"></a>
- **Federal Register notice 2016-22935 · published 2016-09-23 · Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22935.pdf) (`federal-register-2016-22935-6e9cbee524d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2016-22935." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#federal-register-2016-22935-v1 SHA-256: 3c5ba1f5e955dc81306a6482e18f060a3f38243345fd24168f712fd122656db0.

---

<a id="pubmed-pmid-11184472-metreleptin-v1"></a>

## USAN Council. List No.431. New names. Metreleptin.

> PubMed lists PMID 11184472 in Clinical pharmacology and therapeutics as Journal Article, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-11184472-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-11184472-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-11184472-metreleptin-v1
- Content SHA-256: `211630e0d9049d80f69d338dafd6e001e13c38ccf489abfb8d5ff6072d12eb67`

### Claims and source pins

#### Headline

USAN Council. List No.431. New names. Metreleptin. ([`pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee`](#source-pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee))

#### Summary

PubMed lists PMID 11184472 in Clinical pharmacology and therapeutics as Journal Article, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee`](#source-pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee))

#### Paragraph 1

PubMed lists PMID 11184472 in Clinical pharmacology and therapeutics as Journal Article, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee`](#source-pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee`](#source-pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee))

### Sources

<a id="source-pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee"></a>
- **USAN Council. List No.431. New names. Metreleptin. · retained source version 1:2017-11-16:current:4979554b23ee1bd39b28cc79804c87ec03d0db67c4500122ec687cf5b11c5e9d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/11184472/) (`pubmed-observation-pmid-11184472-2017-11-16-4979554b23ee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "USAN Council. List No.431. New names. Metreleptin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-11184472-metreleptin-v1 SHA-256: 211630e0d9049d80f69d338dafd6e001e13c38ccf489abfb8d5ff6072d12eb67.

---

<a id="pubmed-pmid-20350904-metreleptin-v1"></a>

## W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?

> PubMed lists PMID 20350904 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Editorial, Comment, with publication-date metadata of 2010 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20350904-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20350904-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-20350904-metreleptin-v1
- Content SHA-256: `3a1f2c962c2848ec09e866f81aa3b7349f87722c18289cac48556908d606d7f8`

### Claims and source pins

#### Headline

W(h)ither metreleptin for lipodystrophy and the metabolic syndrome? ([`pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e`](#source-pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e))

#### Summary

PubMed lists PMID 20350904 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Editorial, Comment, with publication-date metadata of 2010 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e`](#source-pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e))

#### Paragraph 1

PubMed lists PMID 20350904 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Editorial, Comment, with publication-date metadata of 2010 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e`](#source-pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e`](#source-pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e))

### Sources

<a id="source-pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e"></a>
- **W(h)ither metreleptin for lipodystrophy and the metabolic syndrome? · retained source version 1:2021-02-04:current:1d0c5810f37ea51232730bd8508dbffef20edf2c35fbe307ec82f356a0d2c5e8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20350904/) (`pubmed-observation-pmid-20350904-2021-02-04-1d0c5810f37e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-20350904-metreleptin-v1 SHA-256: 3a1f2c962c2848ec09e866f81aa3b7349f87722c18289cac48556908d606d7f8.

---

<a id="pubmed-pmid-25070319-metreleptin-v1"></a>

## Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.

> PubMed lists PMID 25070319 in The Journal of clinical endocrinology and metabolism as Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2014-07-29 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25070319-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-04-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25070319-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-25070319-metreleptin-v1
- Content SHA-256: `b888d0cfdb0383593a32ba9eed73a095f7525e636dbccabf50c20522aaa1b88b`

### Claims and source pins

#### Headline

Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. ([`pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26`](#source-pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26))

#### Summary

PubMed lists PMID 25070319 in The Journal of clinical endocrinology and metabolism as Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2014-07-29 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26`](#source-pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26))

#### Paragraph 1

PubMed lists PMID 25070319 in The Journal of clinical endocrinology and metabolism as Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2014-07-29 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26`](#source-pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26`](#source-pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26))

### Sources

<a id="source-pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26"></a>
- **Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. · retained source version 1:2023-04-11:current:9a8aac78ae26c44796ed9d86c7d1a50bd5a741b765b813c42ad696a82b936d5e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25070319/) (`pubmed-observation-pmid-25070319-2023-04-11-9a8aac78ae26`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-25070319-metreleptin-v1 SHA-256: b888d0cfdb0383593a32ba9eed73a095f7525e636dbccabf50c20522aaa1b88b.

---

<a id="pubmed-pmid-25581107-metreleptin-v1"></a>

## Metreleptin (Myalept): a leptin analog for generalized lipodystrophy.

> PubMed lists PMID 25581107 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2015-01-19 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25581107-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25581107-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-25581107-metreleptin-v1
- Content SHA-256: `c55ac1bb32d09011a5973c319a705c2b2717d3077faa8d4bd30c0ab1ceb3e7b6`

### Claims and source pins

#### Headline

Metreleptin (Myalept): a leptin analog for generalized lipodystrophy. ([`pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb`](#source-pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb))

#### Summary

PubMed lists PMID 25581107 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2015-01-19 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb`](#source-pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb))

#### Paragraph 1

PubMed lists PMID 25581107 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2015-01-19 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb`](#source-pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb`](#source-pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb))

### Sources

<a id="source-pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb"></a>
- **Metreleptin (Myalept): a leptin analog for generalized lipodystrophy. · retained source version 1:2017-11-16:current:e00746c16fcbe47a47b5ce0d068bab2e1a876fc8ee281e5046b5c667dfc524ec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25581107/) (`pubmed-observation-pmid-25581107-2017-11-16-e00746c16fcb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Metreleptin (Myalept): a leptin analog for generalized lipodystrophy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-25581107-metreleptin-v1 SHA-256: c55ac1bb32d09011a5973c319a705c2b2717d3077faa8d4bd30c0ab1ceb3e7b6.

---

<a id="pubmed-pmid-26063386-metreleptin-v1"></a>

## Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.

> PubMed lists PMID 26063386 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26063386-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26063386-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-26063386-metreleptin-v1
- Content SHA-256: `33f112e8d82ce38a8bd29cd95204104608207fbf982e9095e3915a633aafeb68`

### Claims and source pins

#### Headline

Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. ([`pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df`](#source-pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df))

#### Summary

PubMed lists PMID 26063386 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df`](#source-pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df))

#### Paragraph 1

PubMed lists PMID 26063386 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df`](#source-pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df`](#source-pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df))

### Sources

<a id="source-pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df"></a>
- **Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. · retained source version 1:2018-12-02:current:ff4e82d1a0dfd4bbb54a28e1e5a2169de871c5e22200e18fb5a60c7e1bb6acdb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26063386/) (`pubmed-observation-pmid-26063386-2018-12-02-ff4e82d1a0df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-26063386-metreleptin-v1 SHA-256: 33f112e8d82ce38a8bd29cd95204104608207fbf982e9095e3915a633aafeb68.

---

<a id="pubmed-pmid-26396524-metreleptin-v1"></a>

## New advances in the treatment of generalized lipodystrophy: role of metreleptin.

> PubMed lists PMID 26396524 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2015-09-16 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26396524-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26396524-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-26396524-metreleptin-v1
- Content SHA-256: `7e3c0e4a4dea37d38217724e8fbe5f2b1cdb0b6c09a24168aab698ec1ab3565a`

### Claims and source pins

#### Headline

New advances in the treatment of generalized lipodystrophy: role of metreleptin. ([`pubmed-observation-pmid-26396524-2024-03-23-0514676dda07`](#source-pubmed-observation-pmid-26396524-2024-03-23-0514676dda07))

#### Summary

PubMed lists PMID 26396524 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2015-09-16 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26396524-2024-03-23-0514676dda07`](#source-pubmed-observation-pmid-26396524-2024-03-23-0514676dda07))

#### Paragraph 1

PubMed lists PMID 26396524 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2015-09-16 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26396524-2024-03-23-0514676dda07`](#source-pubmed-observation-pmid-26396524-2024-03-23-0514676dda07))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26396524-2024-03-23-0514676dda07`](#source-pubmed-observation-pmid-26396524-2024-03-23-0514676dda07))

### Sources

<a id="source-pubmed-observation-pmid-26396524-2024-03-23-0514676dda07"></a>
- **New advances in the treatment of generalized lipodystrophy: role of metreleptin. · retained source version 1:2024-03-23:current:0514676dda077b168d5ed9a63dc43224412af683303a799bcbae529f7f6f6d72** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26396524/) (`pubmed-observation-pmid-26396524-2024-03-23-0514676dda07`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "New advances in the treatment of generalized lipodystrophy: role of metreleptin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-26396524-metreleptin-v1 SHA-256: 7e3c0e4a4dea37d38217724e8fbe5f2b1cdb0b6c09a24168aab698ec1ab3565a.

---

<a id="pubmed-pmid-27717125-metreleptin-v1"></a>

## First metreleptin treatment for generalized lipodystrophy in Turkey.

> PubMed lists PMID 27717125 in Diabetes, obesity & metabolism as Case Reports, Letter, with publication-date metadata of 2016-11-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27717125-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27717125-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-27717125-metreleptin-v1
- Content SHA-256: `eeff8d2b63bf5c1e93c686e06517fdb9aed85d116ddce29092159b860f80139b`

### Claims and source pins

#### Headline

First metreleptin treatment for generalized lipodystrophy in Turkey. ([`pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab`](#source-pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab))

#### Summary

PubMed lists PMID 27717125 in Diabetes, obesity & metabolism as Case Reports, Letter, with publication-date metadata of 2016-11-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab`](#source-pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab))

#### Paragraph 1

PubMed lists PMID 27717125 in Diabetes, obesity & metabolism as Case Reports, Letter, with publication-date metadata of 2016-11-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab`](#source-pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab`](#source-pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab))

### Sources

<a id="source-pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab"></a>
- **First metreleptin treatment for generalized lipodystrophy in Turkey. · retained source version 1:2026-01-27:current:8aa206d36eab69da6bcd4579ed2a3e4bca5ff522621b0cc6938a8d13fae5f687** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27717125/) (`pubmed-observation-pmid-27717125-2026-01-27-8aa206d36eab`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "First metreleptin treatment for generalized lipodystrophy in Turkey." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-27717125-metreleptin-v1 SHA-256: eeff8d2b63bf5c1e93c686e06517fdb9aed85d116ddce29092159b860f80139b.

---

<a id="pubmed-pmid-30745727-metreleptin-v1"></a>

## Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report.

> PubMed lists PMID 30745727 in Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology as Journal Article, with publication-date metadata of 2019-01-31 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30745727-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30745727-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-30745727-metreleptin-v1
- Content SHA-256: `9904f6eb51fa02ba688185ba35717b98e9b976da227f5373871bdf578ae25199`

### Claims and source pins

#### Headline

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report. ([`pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d`](#source-pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d))

#### Summary

PubMed lists PMID 30745727 in Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology as Journal Article, with publication-date metadata of 2019-01-31 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d`](#source-pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d))

#### Paragraph 1

PubMed lists PMID 30745727 in Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology as Journal Article, with publication-date metadata of 2019-01-31 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d`](#source-pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d`](#source-pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d))

### Sources

<a id="source-pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d"></a>
- **Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report. · retained source version 1:2020-09-30:current:56409ac4e25dbaa8a605d7ce42cf44975700732a895ef344a4c7633e09e473b2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30745727/) (`pubmed-observation-pmid-30745727-2020-09-30-56409ac4e25d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-30745727-metreleptin-v1 SHA-256: 9904f6eb51fa02ba688185ba35717b98e9b976da227f5373871bdf578ae25199.

---

<a id="pubmed-pmid-30923630-metreleptin-v1"></a>

## Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin.

> PubMed lists PMID 30923630 in Clinical diabetes and endocrinology as Case Reports, Journal Article, with publication-date metadata of 2019-03-14 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30923630-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30923630-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-30923630-metreleptin-v1
- Content SHA-256: `e1621a23ee62d8f97e1762649d921cfa219ce5f48e7a167340152746b5bb999a`

### Claims and source pins

#### Headline

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. ([`pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a`](#source-pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a))

#### Summary

PubMed lists PMID 30923630 in Clinical diabetes and endocrinology as Case Reports, Journal Article, with publication-date metadata of 2019-03-14 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a`](#source-pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a))

#### Paragraph 1

PubMed lists PMID 30923630 in Clinical diabetes and endocrinology as Case Reports, Journal Article, with publication-date metadata of 2019-03-14 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a`](#source-pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a`](#source-pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a))

### Sources

<a id="source-pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a"></a>
- **Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. · retained source version 1:2022-04-08:current:6dea7a511c8a2b37cd1abe375b41b75bb8edfacd58b011405271d67e5748bb7c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30923630/) (`pubmed-observation-pmid-30923630-2022-04-08-6dea7a511c8a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-30923630-metreleptin-v1 SHA-256: e1621a23ee62d8f97e1762649d921cfa219ce5f48e7a167340152746b5bb999a.

---

<a id="pubmed-pmid-31300002-metreleptin-v1"></a>

## Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes.

> PubMed lists PMID 31300002 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-07-12 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31300002-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-04-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31300002-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-31300002-metreleptin-v1
- Content SHA-256: `c892d1386c20d81b187c5d0d3f4c74c3c9f747d29be5769344911dc966b9e53f`

### Claims and source pins

#### Headline

Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. ([`pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7`](#source-pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7))

#### Summary

PubMed lists PMID 31300002 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-07-12 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7`](#source-pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7))

#### Paragraph 1

PubMed lists PMID 31300002 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-07-12 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7`](#source-pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7`](#source-pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7))

### Sources

<a id="source-pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7"></a>
- **Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. · retained source version 1:2020-04-27:current:0bdf624c6ce7456976697ee6c4830fe2a0598a9849f4d2bdb8f15a3fad481611** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31300002/) (`pubmed-observation-pmid-31300002-2020-04-27-0bdf624c6ce7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-31300002-metreleptin-v1 SHA-256: c892d1386c20d81b187c5d0d3f4c74c3c9f747d29be5769344911dc966b9e53f.

---

<a id="pubmed-pmid-33099310-metreleptin-v1"></a>

## Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.

> PubMed lists PMID 33099310 in Italian journal of pediatrics as Case Reports, Journal Article, with publication-date metadata of 2020-10-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33099310-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-08-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33099310-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-33099310-metreleptin-v1
- Content SHA-256: `01775dc86d8abfb1655466e4359cd1fbb4916044f0dc13a98383fa2f278fba53`

### Claims and source pins

#### Headline

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report. ([`pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d`](#source-pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d))

#### Summary

PubMed lists PMID 33099310 in Italian journal of pediatrics as Case Reports, Journal Article, with publication-date metadata of 2020-10-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d`](#source-pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d))

#### Paragraph 1

PubMed lists PMID 33099310 in Italian journal of pediatrics as Case Reports, Journal Article, with publication-date metadata of 2020-10-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d`](#source-pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d`](#source-pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d))

### Sources

<a id="source-pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d"></a>
- **Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report. · retained source version 1:2021-08-26:current:ea193dcbaf0d309516fe08261c17b4af5632d7bd31c25f814c7758ce22437b6d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33099310/) (`pubmed-observation-pmid-33099310-2021-08-26-ea193dcbaf0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-33099310-metreleptin-v1 SHA-256: 01775dc86d8abfb1655466e4359cd1fbb4916044f0dc13a98383fa2f278fba53.

---

<a id="pubmed-pmid-34571177-metreleptin-v1"></a>

## Metreleptin treatment of non-HIV lipodystrophy syndromes.

> PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34571177-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34571177-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-34571177-metreleptin-v1
- Content SHA-256: `e4efd47d60ff8ae0f237bf7187d261b4203896be58b9c39cadf4c300f063f003`

### Claims and source pins

#### Headline

Metreleptin treatment of non-HIV lipodystrophy syndromes. ([`pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745`](#source-pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745))

#### Summary

PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745`](#source-pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745))

#### Paragraph 1

PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745`](#source-pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745`](#source-pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745))

### Sources

<a id="source-pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745"></a>
- **Metreleptin treatment of non-HIV lipodystrophy syndromes. · retained source version 1:2026-11-09:current:92dd720f374578896c5a9aaa9a7c88d8d096164edd4d2343f5cd2592b0bfbd3a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34571177/) (`pubmed-observation-pmid-34571177-2026-11-09-92dd720f3745`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Metreleptin treatment of non-HIV lipodystrophy syndromes." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-34571177-metreleptin-v1 SHA-256: e4efd47d60ff8ae0f237bf7187d261b4203896be58b9c39cadf4c300f063f003.

---

<a id="pubmed-pmid-40860570-metreleptin-v1"></a>

## Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2.

> PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40860570-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40860570-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-40860570-metreleptin-v1
- Content SHA-256: `7034a1d0d5de8041933261cb9dc1a659cc2bc62bf52de53c79e8fceb7c387d54`

### Claims and source pins

#### Headline

Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2. ([`pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b`](#source-pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b))

#### Summary

PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b`](#source-pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b))

#### Paragraph 1

PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b`](#source-pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b`](#source-pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b))

### Sources

<a id="source-pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b"></a>
- **Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2. · retained source version 1:2025-09-14:current:c0dad1492d2bd6955cd26a680d36a198f73799b802ab9d1d9e9f2be08dd651f6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40860570/) (`pubmed-observation-pmid-40860570-2025-09-14-c0dad1492d2b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-40860570-metreleptin-v1 SHA-256: 7034a1d0d5de8041933261cb9dc1a659cc2bc62bf52de53c79e8fceb7c387d54.

---

<a id="pubmed-pmid-41080980-metreleptin-v1"></a>

## Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.

> PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41080980-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-10-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41080980-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-41080980-metreleptin-v1
- Content SHA-256: `29e4628318ca4aacefaceeae64af40e685366dfdd6c9531c8e4ab730abfc7fb7`

### Claims and source pins

#### Headline

Metreleptin In SHORT Syndrome With Uncontrolled Diabetes. ([`pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb`](#source-pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb))

#### Summary

PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb`](#source-pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb))

#### Paragraph 1

PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb`](#source-pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb`](#source-pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb))

### Sources

<a id="source-pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb"></a>
- **Metreleptin In SHORT Syndrome With Uncontrolled Diabetes. · retained source version 1:2025-10-15:current:853ee76241eb30f6e5461ef60bb62a9148edbdea25dd71d3d6cf396f41fe095f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41080980/) (`pubmed-observation-pmid-41080980-2025-10-15-853ee76241eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Metreleptin In SHORT Syndrome With Uncontrolled Diabetes." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-41080980-metreleptin-v1 SHA-256: 29e4628318ca4aacefaceeae64af40e685366dfdd6c9531c8e4ab730abfc7fb7.

---

<a id="pubmed-pmid-42222073-metreleptin-v1"></a>

## Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.

> PubMed lists PMID 42222073 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42222073-metreleptin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42222073-metreleptin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-42222073-metreleptin-v1
- Content SHA-256: `342e446a0a14b64b536c717f7b4d684429be4f2161e5e9f50aaf8323e2a582b5`

### Claims and source pins

#### Headline

Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date. ([`pubmed-observation-pmid-42222073-2026-08-13-289aa023c008`](#source-pubmed-observation-pmid-42222073-2026-08-13-289aa023c008))

#### Summary

PubMed lists PMID 42222073 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42222073-2026-08-13-289aa023c008`](#source-pubmed-observation-pmid-42222073-2026-08-13-289aa023c008))

#### Paragraph 1

PubMed lists PMID 42222073 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42222073-2026-08-13-289aa023c008`](#source-pubmed-observation-pmid-42222073-2026-08-13-289aa023c008))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42222073-2026-08-13-289aa023c008`](#source-pubmed-observation-pmid-42222073-2026-08-13-289aa023c008))

### Sources

<a id="source-pubmed-observation-pmid-42222073-2026-08-13-289aa023c008"></a>
- **Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date. · retained source version 1:2026-08-13:current:289aa023c00834affe07cc8eb8d20a123715d63f2eb799abc0bd59f1eb3ca2cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42222073/) (`pubmed-observation-pmid-42222073-2026-08-13-289aa023c008`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/metreleptin.json#pubmed-pmid-42222073-metreleptin-v1 SHA-256: 342e446a0a14b64b536c717f7b4d684429be4f2161e5e9f50aaf8323e2a582b5.

